All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 14th May 2017, the “Role of the B-Cell Receptor and Other Signaling Pathways in CLL” took place at iwCLL, and was co-chaired by Nicholas Chiorazzi (The Feinstein Institute for Medical Research, Manhasset, NY, USA) and Kostas Stamatopoulos (Center for Research and Technology Hellas, Thessaloniki, Greece).
“Intraclonal Diversification and Evolution in Chronic Lymphocytic Leukemia Patients by High-Throughput Sequencing of IGHV-D-J Rearrangements” was a talk presented during this session by Davide Bagnara from the University of Genova, Italy.
It has been previously reported in Sanger sequencing studies than IGHV-D-J of CLL clones can undergo intra-clonal heterogeneity.
This group performed high-throughput sequencing on the IGHV-D-J repertoire of FACS sorted CD19+CD5+ cells from 39 patients with treatment naïve CLL. From mRNA, and using a set of primers covering every IGHV gene, full-length IGHV-D-J repertoire was amplified. Unique Molecular Identifiers (for error) and Polymerase Chain Reaction (for correction) were used to prepare libraries. The CD19+CD5+ compartment in patients with CLL contains both leukemic and non-leukemia B-cell clones.
In conclusion, CLL clones diversify in vivo, acquiring IGHV-D-J mutations resulting in a level of clonal complexity not fully comprehended thus far, and takes place in both U- and M-CLL. The group hypothesized that the ongoing evolution of IGHV-D-J is likely due to Activation Induced Deaminase. Moreover, they suggested that ongoing IGHV-D-J could be used as a marker of DNA changes taking place across the genome and so presents as a measure of genomic instability.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox